welcome
CNBC

CNBC

Health

Health

Healthy Returns: AstraZeneca cholesterol pill shows promise as race with Merck heats up

CNBC
Summary
Nutrition label

83% Informative

AstraZeneca and Merck are the main drugmakers testing oral versions of PCSK9 Inhibitors , which reduce levels of low-density lipoprotein (LDL) cholesterol, or "bad" cholesterol.

High LDL cholesterol is the top driver of cardiovascular events such as heart attacks and strokes.

More than 70% of patients taking statins aren't reaching the target level for cholesterol.

23andMe went public in 2021 via a merger with a special purpose acquisition company.

Anne Wojcicki , who resigned as CEO last month , said she will pursue the company as an independent bidder.

DNA data is particularly sensitive because each person's sequence is unique, meaning it can never be fully anonymized.

VR Score

86

Informative language

90

Neutral language

19

Article tone

informal

Language

English

Language complexity

56

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

short-lived

Source diversity

2

Affiliate links

no affiliate links